

# **Three Techniques for Rigorous Analysis of Intensive Within-person Experiments**

Ty A. Ridenour, Ph.D., M.P.E.

Behavioral Health Epidemiology, Research Triangle Institute Center on Education and Drug Abuse Research, U. Pittsburgh

> Collaborators: Hsin-Yi Liu, Rory Cooper Funded by NIDA (P50-005605) Thanks to Thomas Pineo, Kay Chen, Katya Hill

#### Outline

\* Thorough clinical research requires intensive, idiographic trials

\* Three rigorous analytic techniques

\* Three clinical trials using those techniques



## **Clinician's Dilemma**



**Figure 1**—Effect sizes for parallel design studies. Studies are presented in increasing order of chronology from the bottom, with primary authors' names along the left side of the graph. \*Mean effect size. Bars denote the 95% CIs of the mean. Mean effect size for the 11 studies was d = 0.95.

From: Weissberg-Benchell et al., 03



## **Clinician's Dilemma**



**Figure 1**—Effect sizes for parallel design studies. Studies are presented in increasing order of chronology from the bottom, with primary authors' names along the left side of the graph. \*Mean effect size. Bars denote the 95% CIs of the mean. Mean effect size for the 11 studies was d = 0.95.

From: Weissberg-Benchell et al., 03



### **Needs for Idiographic Clinical Trials**

- **Rare or newly discovered illness**
- Intervention mechanisms / processes
- Small population or available sample
- **Pilot studies**
- In-the-field research required
- **Resolving clinician's dilemma**
- **Quantifying clinician observation**
- Lack of funding, infrastructure
- Patients have study exclusion criteria



### **Needs for Idiographic Clinical Trials**

**Rare or newly discovered illness** 

- Intervention mechanisms / processes
- **Small population or available sample**
- **Pilot studies**
- **In-the-field research required**
- **Resolving clinician's dilemma**
- **Quantifying clinician observation**
- Lack of funding, research infrastructure
- Patients have study exclusion criteria

Dr. Thomas Pineo: How to help nursing home residents with diabetes?



# Analytic Methods with Promise for Idiographic Clinical Trials

#### Time Series Analysis From: Econometrics (Chatfield, 2004)

#### State-Space Modeling From: Mathematics, Physics (Molenaar, 2003)

Trajectory Analysis From: Social Sciences (Ridenour et al., 2012)



### **Examples of Models**



#### **Trajectory Analysis**





Tarter et al., 2012



Patient A	8/1/05	8/8/05	8/15/05	8/22/05	8/29/05	9/5/05	9/12/05	g/19/05	6 9/26/05	တ္ <mark>ဂ</mark> 10/3/05	တ္ <mark>ပ</mark> 10/10/05	တ္ <mark>ပ</mark> 10/17/05	D 10/24/05	ဂ္ဂ 10/31/05	ရ <mark>ှ</mark> 11/7/05	g 11/14/05	တ <mark>ြ</mark> 11/21/05	တ္ <mark>ပ</mark> 11/28/05	ဂ္ဂ 12/5/05	ဂ္ဂ ဂ	တ္ <mark>ပ</mark> 12/19/05	တ္တ ရာ 12/26/05													
Patient B	SS	SS	SS	SS	SS	SS	ss	GG	GG	GG	GG	GG	GG	GG	GG	GG	GG	GG	GG	GG	GG	GG													
Patient C Patient D																							 												
							1																												
					10/2/06	10/9/06	10/16/06	10/23/06	10/30/06	11/6/06	11/13/06	11/20/06	11/27/06	12/4/06	12/11/06	12/18/06	12/25/06	1/1/07	1/8/07	1/15/07	1/22/07	1/29/07	2/5/07	2/12/07	2/19/07	2/26/07	3/5/07	3/12/07	3/19/07	3/26/07	4/2/07	4/9/07	4/16/07	4/23/07	4/30/07
	Patie	ent A	1																																
	Patie Patie Patie	ent B ent C ent D	3 )	 	SS	SS	SS	SS	SS SS	I SS I SS	<u>GG</u> ss	GG ss	GG ss	<u>GG</u> ss	i GG sG	GG GG	GG GG	GG GG	GG GG	GG GG	GG GG	GG GG	GG GG	GG ( GG (	GG ( GG (	GG GG (	GG	GG	GG	GG (	GG	GG	GG	GG	G
															i																				

н



Ridenour et al., 2013



#### **Pineo's Patient B**





#### P-Technique



11

	Aggregated Times <sup>A</sup>	7:30am	11:30am	4:30pm	8:30pm	ARIMA	
MMTA, Entire Comela	-49.4ª	-35.9 <sup>b</sup>	-43.3 <sup>a*</sup>	-59.4 <sup>b</sup>	-59.1 <sup>a*</sup>	-52.2	
MINITA; Entire Sample	(9.2)	(9.8)	(194.2)	(9.7)	(277.9)	(22.6)	
MATA af Dation ( A	-40.9 <sup>b</sup>	0.2 <sup>b</sup> *	<b>1.8</b> <sup>a*</sup>	-50.4 <sup>b</sup>	-104.2 <sup>b</sup>	<b>0</b> ⊏ <b>0</b> *	
MINITA of Patient A	(10.7)	(11.1)	(24.4)	(20.2)	(19.4)	-25.2*	
MMTA of Dations P	-107.9 <sup>b</sup>	-32.2 <sup>b</sup>	-117.3ª	-156.3 <sup>b</sup>	-122.2 <sup>b</sup>	60 E	
WINITA OF Patient B	(11.8)	(8.8)	(23.0)	(19.3)	(17.0)	-02.5	
MMTA of Patient C	-22.6 <sup>b*</sup>	-22.6 <sup>b*</sup> 11.5 <sup>b*</sup> -66.6 <sup>a</sup>		-35.5 <sup>b*</sup>	3.0 <sup>b*</sup>	17.0*	
WIWITA OF Latient C	(15.3)	(27.5)	(26.8)	(25.4)	(27.7)	-47.9	
MMTA of Patient D	-24.6 <sup>b</sup>	-112.1 <sup>b</sup>	26.3 <sup>a*</sup>	43.5 <sup>b</sup>	-57.3 <sup>b</sup>	<b>n</b> /2	
WIWITA OF LATIENT D	(10.1)	(16.0)	(17.6)	(17.7)	(24.3)	11/a	
P-technique; Entire	-64.9	-32.4	-89.3	-98.8	-83.1		
Sample	(6.8)	(7.7)	(7.6)	(6.5)	(6.2)		

Note: A = intervention effect aggregated over all times of the day for the sample or specific patient. a = heterogeneous autoregression, lag 2, error covariance structure. b = factor analytic, lag 2, error covariance structure. \*Change in glucose was NS (p>.01). Parenthetical values are standard errors. Change attributable to time (slope) and time-intervention interaction were statistically nonsignificant in all MMTA.



	Aggregated Times <sup>A</sup>	7:30am	11:30am	4:30pm	8:30pm	ARIMA	
MMTA Estina Comple	<b>-49.4</b> ª	-35.9 <sup>b</sup>	-43.3 <sup>a*</sup>	-59.4 <sup>b</sup>	-59.1 <sup>a*</sup>	-52.2	
MINITA; Entire Sample	(9.2)	(9.8)	(194.2)	(9.7)	(277.9)	(22.6)	
MATA - CD-Cont A	-40.9 <sup>b</sup>	0.2 <sup>b</sup> *	<b>1.8</b> <sup>a*</sup>	-50.4 <sup>b</sup>	-104.2 <sup>b</sup>	0F 0*	
MINITA of Patient A	(10.7)	(11.1)	(24.4)	(20.2)	(19.4)	-25.2	
MMTA of Dationt P	-107.9 <sup>b</sup>	-32.2 <sup>b</sup>	-117.3ª	-156.3 <sup>b</sup>	-122.2 <sup>b</sup>	60 E	
WIWITA OF Fatient B	(11.8)	(8.8)	(23.0)	(19.3)	(17.0)	-02.5	
MMTA of Patient C	-22.6 <sup>b*</sup>	11.5 <sup>b*</sup>	<b>-66.6</b> <sup>a</sup>	-35.5 <sup>b*</sup>	3.0 <sup>b*</sup>	_17 0*	
WIWITA OF Latient C	(15.3)	(27.5)	(26.8)	(25.4)	(27.7)	-47.9	
MMTA of Patient D	-24.6 <sup>b</sup>	-112.1 <sup>b</sup>	26.3 <sup>a*</sup>	43.5 <sup>b</sup>	-57.3 <sup>b</sup>	n/2	
WIWITA OF LATERT D	(10.1)	(16.0)	(17.6)	(17.7)	(24.3)	11/a	
P-technique; Entire	-64.9	-32.4	-89.3	-98.8	-83.1		
Sample	(6.8)	(7.7)	(7.6)	(6.5)	(6.2)		

Note: A = intervention effect aggregated over all times of the day for the sample or specific patient. a = heterogeneous autoregression, lag 2, error covariance structure. b = factor analytic, lag 2, error covariance structure. \*Change in glucose was NS (p>.01). Parenthetical values are standard errors. Change attributable to time (slope) and time-intervention interaction were statistically nonsignificant in all MMTA.



	Trajectory Analysis	Time Series / ARIMA	State-space / P-technique
Strengths:	Can model small time series	Models serial dependence	Best reproduction of observed data
	Simplest	Best isolation of efficacy	Easily tests intervention effect on variance
	Most flexible	Can forecast	Mimics large 'N' SEM
	Statistical power		
	Also used with large samples		
Limitations:	Limited serial dependence	Easily made unstable	Easily made unstable
	Coarsest estimate of efficacy	Requires many observations	Requires many observations
			Models are complex



From: Ding et al., 2010







From: Ding et al., 2010





#### **Instruction Only**

#### **Instruction + Virtual Coach**





	Mean	Standard Deviation	Cohen's d Compared to Baseline
BASELINE (244 observations)			
General Discomfort	41.9	12.39	n/a
Frequency of Use	2.1	2.36	n/a
Duration of Use in Mod/Max 2	50.8	44.78	n/a
Discomfort Intensity	19.2	9.52	n/a
INSTRUCTION (561 observations)			
General Discomfort	42.6	13.01	
Frequency of Use <sup>B</sup>	1.5	2.09	0.28
Duration of Use in Mod/Max $2^{B}$	37.6	46.02	0.29
Discomfort Intensity	19.9	9.36	
VIRTUAL COACH (262 observations)			
General Discomfort	42.3	10.81	
Frequency of Use <sup>B,I</sup>	3.3	3.02	0.44
Duration of Use in Mod/Max $2^{B,I}$	67.4	45.73	0.37
Discomfort Intensity <sup>B,I</sup>	10.7	5.52	1.10
Note: <sup>B</sup> Differs from Baseline phase ( $p < .001$	). <sup>I</sup> Differs from	n Instruction phas	se (p<.001).



# Cooper & Liu's Clinician's Dilemma: Virtual Coach Outcomes

	Mean	Standard Deviation	Cohen's d Compared to Baseline			
BASELINE (244 observations)						
General Discomfort	41.9	12.39	n/a			
Frequency of Use	2.1	2.36	n/a			
Duration of Use in Mod/Max 2	50.8	44.78	n/a			
Discomfort Intensity	19.2	9.52	n/a			
INSTRUCTION (561 observations)						
General Discomfort	42.6	13.01				
Frequency of Use <sup>B</sup>	1.5	2.09	0.28			
Duration of Use in Mod/Max $2^{B}$	37.6	46.02	0.29			
Discomfort Intensity	19.9	9.36				
VIRTUAL COACH (262 observations)						
General Discomfort	42.3	10.81				
Frequency of Use <sup>B,I</sup>			0.44			
Duration of Use in Mod/Max $2^{B,I}$			0.37			
Discomfort Intensity <sup>B,I</sup>	10.7	5.52	1.10			
Note: <sup>B</sup> Differs from Baseline phase ( $p < .001$ ). <sup>I</sup> Differs from Instruction phase ( $p < .001$ ).						



# Cooper & Liu's Clinician's Dilemma: Competing Models Relating Discomfort to PSF Usage



### Intervention Process: Discomfort with PSF Usage





### Intervention Process: Discomfort with PSF Usage





### Intervention Process: Discomfort with PSF Usage





### Review

\* Needs for idiographic clinical trial designs

Mixed model trajectory analysis
State-space modeling
Time series analysis

\* Blood sugar, speech acquisition, treatment compliance



#### **Next Steps**

\* Create tools to support using analytic techniques more widely in idiographic clinical trials

\* Numerous specific advances within the particular analytic techniques (e.g., using more complex USEM)

\* Demonstrate idiographic clinical trial techniques in a range of fields



#### References

- Chatfield, C. The Analysis of Time Series (6<sup>th</sup> ed.). Chapman & Hall/CRC, Boca Raton, FL. 2004.
- Molenaar, P.C.M. A manifesto on psychology as idiographic science: Brining the person back into scientific psychology, this time forever. Measurement 2004; 2: 201-218. Molenaar, Peter CM, Richard M. Lerner, and Karl M. Newell, eds. Handbook of developmental systems theory and methodology. Guilford Publications, 2013. Ridenour, TA, Hall, DL, Bost, JE. A small sample randomized clinical trial methodology using N-of-1 designs and mixed model analysis. American Journal of Drug and Alcohol Abuse 2009; 35: 260-266.
- Ridenour TA, Pineo TZ, Maldonado-Molina MM, Hassmiller-Lich, K: Toward idiographic research in prevention science: Demonstration of three techniques for rigorous small sample research. Prevention Science 2013; 14: 267-278.
- Sterman, J.D. Business Dynamics: Systems Thinking and Modeling for a Complex World. Irwin McGraw-Hill: Boston, MA. 2000.
- Tarter RE, Kirisci L, Ridenour TA, Bogen D. Application of person-centered medicine in addiction. International Journal of Person Centered Medicine 2012; 2: 240-249.

